Key Takeaways
- • Forbion has invested in 10 North American companies since opening its first U.S. office in Boston, with 9 of those 10 deals completed in 2025 and 2026, demonstrating accelerated deployment in the region.
- • The firm appointed Regina Salvat, PhD, as Principal in the Boston office and hired Josh Brumm, the former CEO of Dyne Therapeutics, as a biotech industry leader to strengthen U.S. market presence.
- • Forbion manages just over €5 billion in assets and operates across three offices globally (The Netherlands, Germany, and the U.S.), positioning itself as a leading life sciences venture capital firm with deep European expertise expanding into North America.
- • The Boston office opening represents a strategic expansion for Forbion to support its existing portfolio companies in both Europe and North America, capitalizing on the region's biotech cluster and innovation ecosystem.
Summary
Forbion, a leading European life sciences venture capital firm managing over €5 billion in assets, is significantly expanding its U.S. footprint with the establishment of a Boston office and targeted senior hires. The firm has already deployed capital across 10 North American companies since entering the market, with 9 of those investments closed during 2025 and 2026, indicating an accelerated commitment to the region during a period of broader biotech sector volatility.
To lead this expansion, Forbion appointed Regina Salvat, PhD, as Principal in the Boston office and recruited Josh Brumm, former CEO of Dyne Therapeutics, as a biotech industry leader. These strategic hires reflect the firm's effort to build credibility and operational expertise within the competitive U.S. life sciences market, leveraging both domain-specific knowledge and established relationships within the biotech ecosystem.
According to Martien van Osch, Co-Founder of Forbion, the Boston office opening represents a natural next step for the firm, enabling better support of its existing portfolio companies across both European and North American markets. The firm currently operates as a team of over 50 professionals across offices in The Netherlands, Germany, and the newly established Boston location. The concentration of Forbion's North American deal activity in the most recent two years suggests the firm is actively building momentum in the region and positioning itself to compete with established U.S.-focused life sciences venture capital platforms.
To lead this expansion, Forbion appointed Regina Salvat, PhD, as Principal in the Boston office and recruited Josh Brumm, former CEO of Dyne Therapeutics, as a biotech industry leader. These strategic hires reflect the firm's effort to build credibility and operational expertise within the competitive U.S. life sciences market, leveraging both domain-specific knowledge and established relationships within the biotech ecosystem.
According to Martien van Osch, Co-Founder of Forbion, the Boston office opening represents a natural next step for the firm, enabling better support of its existing portfolio companies across both European and North American markets. The firm currently operates as a team of over 50 professionals across offices in The Netherlands, Germany, and the newly established Boston location. The concentration of Forbion's North American deal activity in the most recent two years suggests the firm is actively building momentum in the region and positioning itself to compete with established U.S.-focused life sciences venture capital platforms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.